US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by BioNTech SE

< Previous 1 2 3 4 Next >
News headline image
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Host Innovation Series R&D Day on November 11, 2025
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
News headline image
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
< Previous 1 2 3 4 Next >